These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 36735581)

  • 1. Chemical Modifications and Design Influence the Potency of
    Saher O; Zaghloul EM; Umek T; Hagey DW; Mozafari N; Danielsen MB; Gouda AS; Lundin KE; Jørgensen PT; Wengel J; Smith CIE; Zain R
    Nucleic Acid Ther; 2023 Apr; 33(2):117-131. PubMed ID: 36735581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oligonucleotides Targeting DNA Repeats Downregulate
    Umek T; Olsson T; Gissberg O; Saher O; Zaghloul EM; Lundin KE; Wengel J; Hanse E; Zetterberg H; Vizlin-Hodzic D; Smith CIE; Zain R
    Nucleic Acid Ther; 2021 Dec; 31(6):443-456. PubMed ID: 34520257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lowering Mutant Huntingtin Using Tricyclo-DNA Antisense Oligonucleotides As a Therapeutic Approach for Huntington's Disease.
    Imbert M; Blandel F; Leumann C; Garcia L; Goyenvalle A
    Nucleic Acid Ther; 2019 Oct; 29(5):256-265. PubMed ID: 31184975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting CAG repeat RNAs reduces Huntington's disease phenotype independently of huntingtin levels.
    Rué L; Bañez-Coronel M; Creus-Muncunill J; Giralt A; Alcalá-Vida R; Mentxaka G; Kagerbauer B; Zomeño-Abellán MT; Aranda Z; Venturi V; Pérez-Navarro E; Estivill X; Martí E
    J Clin Invest; 2016 Nov; 126(11):4319-4330. PubMed ID: 27721240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat.
    Gagnon KT; Pendergraff HM; Deleavey GF; Swayze EE; Potier P; Randolph J; Roesch EB; Chattopadhyaya J; Damha MJ; Bennett CF; Montaillier C; Lemaitre M; Corey DR
    Biochemistry; 2010 Nov; 49(47):10166-78. PubMed ID: 21028906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CTG repeat-targeting oligonucleotides for down-regulating Huntingtin expression.
    Zaghloul EM; Gissberg O; Moreno PMD; Siggens L; Hällbrink M; Jørgensen AS; Ekwall K; Zain R; Wengel J; Lundin KE; Smith CIE
    Nucleic Acids Res; 2017 May; 45(9):5153-5169. PubMed ID: 28334749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphorodiamidate morpholino oligomers suppress mutant huntingtin expression and attenuate neurotoxicity.
    Sun X; Marque LO; Cordner Z; Pruitt JL; Bhat M; Li PP; Kannan G; Ladenheim EE; Moran TH; Margolis RL; Rudnicki DD
    Hum Mol Genet; 2014 Dec; 23(23):6302-17. PubMed ID: 25035419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of 2'-O-methyl/thiophosphonoacetate-modified antisense oligonucleotides on huntingtin expression in patient-derived cells.
    Matsui M; Threlfall RN; Caruthers MH; Corey DR
    Artif DNA PNA XNA; 2014 Dec; 5(3):e1146391. PubMed ID: 26865404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Translating Antisense Technology into a Treatment for Huntington's Disease.
    Lane RM; Smith A; Baumann T; Gleichmann M; Norris D; Bennett CF; Kordasiewicz H
    Methods Mol Biol; 2018; 1780():497-523. PubMed ID: 29856033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities.
    Tabrizi SJ; Estevez-Fraga C; van Roon-Mom WMC; Flower MD; Scahill RI; Wild EJ; Muñoz-Sanjuan I; Sampaio C; Rosser AE; Leavitt BR
    Lancet Neurol; 2022 Jul; 21(7):645-658. PubMed ID: 35716694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nucleic Acid Therapeutics in Huntington's Disease.
    Singh K; Roy I
    Recent Pat Biotechnol; 2019; 13(3):187-206. PubMed ID: 30747088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preventing formation of toxic N-terminal huntingtin fragments through antisense oligonucleotide-mediated protein modification.
    Evers MM; Tran HD; Zalachoras I; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
    Nucleic Acid Ther; 2014 Feb; 24(1):4-12. PubMed ID: 24380395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allele-selective inhibition of mutant huntingtin by peptide nucleic acid-peptide conjugates, locked nucleic acid, and small interfering RNA.
    Hu J; Matsui M; Corey DR
    Ann N Y Acad Sci; 2009 Sep; 1175():24-31. PubMed ID: 19796074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interrupting sequence variants and age of onset in Huntington's disease: clinical implications and emerging therapies.
    Wright GEB; Black HF; Collins JA; Gall-Duncan T; Caron NS; Pearson CE; Hayden MR
    Lancet Neurol; 2020 Nov; 19(11):930-939. PubMed ID: 33098802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin.
    Carroll JB; Warby SC; Southwell AL; Doty CN; Greenlee S; Skotte N; Hung G; Bennett CF; Freier SM; Hayden MR
    Mol Ther; 2011 Dec; 19(12):2178-85. PubMed ID: 21971427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The length of uninterrupted CAG repeats in stem regions of repeat disease associated hairpins determines the amount of short CAG oligonucleotides that are toxic to cells through RNA interference.
    Murmann AE; Patel M; Jeong SY; Bartom ET; Jennifer Morton A; Peter ME
    Cell Death Dis; 2022 Dec; 13(12):1078. PubMed ID: 36585400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent and sustained cellular inhibition of miR-122 by lysine-derivatized peptide nucleic acids (PNA) and phosphorothioate locked nucleic acid (LNA)/2'-O-methyl (OMe) mixmer anti-miRs in the absence of transfection agents.
    Torres AG; Threlfall RN; Gait MJ
    Artif DNA PNA XNA; 2011; 2(3):71-8. PubMed ID: 22567190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Huntingtin Haplotypes Provide Prioritized Target Panels for Allele-specific Silencing in Huntington Disease Patients of European Ancestry.
    Kay C; Collins JA; Skotte NH; Southwell AL; Warby SC; Caron NS; Doty CN; Nguyen B; Griguoli A; Ross CJ; Squitieri F; Hayden MR
    Mol Ther; 2015 Nov; 23(11):1759-1771. PubMed ID: 26201449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological activity and biotechnological aspects of locked nucleic acids.
    Lundin KE; Højland T; Hansen BR; Persson R; Bramsen JB; Kjems J; Koch T; Wengel J; Smith CI
    Adv Genet; 2013; 82():47-107. PubMed ID: 23721720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient and Precise Processing of the Optimized Primary Artificial MicroRNA in a Huntingtin-Lowering Adeno-Associated Viral Gene Therapy
    Wang W; Zhou P; Wang X; Chen F; Christensen E; Thompson J; Ren X; Kells A; Stanek L; Carter T; Hou J; Sah DWY
    Hum Gene Ther; 2022 Jan; 33(1-2):37-60. PubMed ID: 34806402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.